# Eckard Weber

> Eckard Weber is a Series B investor at Domain Associates backing Health Care and Biotechnology. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Domain Associates](https://shizune.co/investors/profile/domain-associates)
- Location: San Diego, United States
- Total investments: 8
- Last investment: Jan 2014
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eckard-weber-75428911

Eckard Weber is a Series B investor at Domain Associates in San Diego focused on Health Care and Biotechnology. Eckard Weber is aVenture Partner at Canaan Partners and he is also an Advisory Partner at Domain Associates. He holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 50% |
| Biotechnology | 4 | 50% |
| Medical | 2 | 25% |
| Therapeutics | 2 | 25% |
| Pharmaceutical | 2 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 38% |
| Series A | 2 | 25% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Atara Biotherapeutics | Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, andmanufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com. | $13.5M | Series B | Jan 10, 2014 |  |
| Atara Biotherapeutics | Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, andmanufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com. | $38.5M | Series B | Dec 17, 2013 |  |
| Tobira Therapeutics | Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey. | $31M | Series B | Sep 29, 2010 |  |
| Adastra Pharmaceuticals | Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting importantcyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients.Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California. | $5M |  | Apr 15, 2010 |  |
| Adastra Pharmaceuticals | Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting importantcyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients.Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California. | $40M | Series A | Mar 15, 2007 |  |
| Imagine Pharma | Imagine Pharma is a drug discovery and development company that focuses on innovative regenerative approaches to therapeutic drugs for diabetes and cardiovascular disease. Their agile, creative and efficient approach to drug discovery is designed to find therapeutics that significantly improve on the efficacy and safety of existing treatments. | $3.7M | Series A | Apr 27, 2004 |  |
| Peninsula Pharmaceuticals | Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets. Peninsula's lead product candidate, doripenem, is a broad-spectrumantibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections. | $57.9M | Series C | Jan 16, 2004 |  |
| Peninsula Pharmaceuticals | Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets. Peninsula's lead product candidate, doripenem, is a broad-spectrumantibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections. | $22.1M | Series B | Oct 28, 2002 |  |

8 of 8 investments shown.

## Co-investors
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 3 deals together
- [Montreux Equity Partners](https://shizune.co/investors/profile/montreaux-equity-partners) — VC Fund, 3 deals together
- [Alexandria](https://shizune.co/investors/profile/alexandria-venture) — VC Fund, 2 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [A. M. Pappas & Associates](https://shizune.co/investors/profile/a-m-pappas-associates) — VC Fund, 2 deals together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 2 deals together

## About Domain Associates

VC Fund · San Diego, United States

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

5 contacts available at Domain Associates.

| Name | Title | Profile |
| --- | --- | --- |
| Brian Dovey | Partner | https://shizune.co/investors/profile/brian-dovey |
| Brian Halak | Partner | https://shizune.co/investors/profile/brian-k-halak |
| Dennis Podlesak | Venture Capitalist | https://shizune.co/investors/profile/dennis-podlesak |
| Eckard Weber | Partner | https://shizune.co/investors/profile/eckard-weber |
| Jesse I. Treu | Founding Partner | https://shizune.co/investors/profile/jesse-i-treu |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eckard Weber invest in?

Eckard Weber invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eckard Weber last invest?

The most recent investment recorded for Eckard Weber closed in Jan 2014. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co